Credit Suisse Ag Arcutis Biotherapeutics, Inc. Transaction History

Credit Suisse Ag

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$5.31 - $10.98 $110,421 - $228,329	-20,795 Reduced 26.57%	57,477 $305,000
Q2 2023 Aug 11, 2023	BUY	$7.51 - $15.0 $321,240 - $641,625	42,775 Added 120.5%	78,272 $745,000
Q1 2023 May 10, 2023	BUY	$10.23 - $17.14 $112 - $188	11 Added 0.03%	35,497 $390,000
Q4 2022 Feb 13, 2023	BUY	$13.96 - $20.4 $8,836 - $12,913	633 Added 1.82%	35,486 $525,000
Q3 2022 Nov 10, 2022	BUY	$17.85 - $26.95 $305,449 - $461,168	17,112 Added 96.45%	34,853 $665,000

Q2 2022 Aug 12, 2022	BUY	$16.33 - $22.2 $8,197 - $11,144	502 Added 2.91%	17,741 $378,000
Q1 2022 May 16, 2022	SELL	$14.38 - $22.79 $5,809 - $9,207	-404 Reduced 2.29%	17,239 $331,000
Q4 2021 Feb 14, 2022	BUY	$14.98 - $25.5 $9,766 - $16,626	652 Added 3.84%	17,643 $366,000
Q3 2021 Nov 12, 2021	BUY	$19.28 - $27.1 $45,635 - $64,145	2,367 Added 16.19%	16,991 $406,000
Q2 2021 Aug 16, 2021	SELL	$24.42 - $34.75 $50,134 - $71,341	-2,053 Reduced 12.31%	14,624 $400,000
Q1 2021 May 14, 2021	SELL	$24.47 - $36.98 $194,316 - $293,658	-7,941 Reduced 32.26%	16,677 $482,000
Q4 2020 Feb 12, 2021	BUY	$17.82 - $31.73 $438,692 - $781,129	24,618 New	24,618 $692,000

172

126M

498K

1.64M

Ticker ARQT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,187,500
Market Cap $560M
Description
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

Stay updated on Credit Suisse Ag with notifications on news.